Compare Keysight Technologies Inc (KEYS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Keysight Technologies Inc vs TG Therapeutics Inc — how do they compare? Keysight Technologies Inc trades at $344 (market cap $58.74B), while TG Therapeutics Inc trades at $49.44 (market cap $7.64B). The key difference: Keysight Technologies Inc is far larger — about 7.7× TG Therapeutics Inc's market cap, and Keysight Technologies Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| KEYS | TGTX | |
|---|---|---|
Market Cap | $58.74B | $7.64B |
Sector | Technology | Health |
52-Week High | $373.34 | $59.06 |
52-Week Low | $158.51 | $26.94 |
Enterprise Value | $59.08B | $7.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Keysight Technologies (KEYS) trades at $354.38, up 5.66% with strong bullish momentum. The stock shows robust fundamentals with revenue of $5.38B and net income of $850M in 2025, supported by consistent earnings beats. Technical indicators signal bullish trends with moving averages supporting upward momentum, while RSI suggests mild overbought conditions. Recent news highlights institutional buying and product innovations in 5G and photonics.
Outlook remains positive with analyst consensus at Buy (81%) and $396.56 price target, offering ~12% upside. Risks include elevated valuation multiples (P/E 55.35) and competitive pressures in tech instruments. Earnings growth and strategic acquisitions position KEYS for continued strength, though investors should monitor execution on $6.1B revenue guidance for 2026.
TG Therapeutics (TGTX) trades at $49.50, up 0.69% today, with a bearish technical signal from moving averages despite neutral oscillators. The company reported strong revenue growth, with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though it missed earnings estimates for three consecutive quarters. Profitability metrics remain robust with a net income margin of 55.22% and ROE exceeding 100%, but valuation ratios like EV/EBITDA at 56.26 suggest premium pricing.
The outlook is mixed: bullish analyst sentiment with an 84.6% buy rating and a $63.75 price target offers upside potential, driven by Briumvi's commercial success and expansion into schizophrenia trials. However, risks include earnings misses, a shareholder investigation into fiduciary duties, and high cash burn in 2025. Investors should weigh strong revenue momentum against execution risks and elevated valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Keysight Technologies Inc
Keysight Technologies is a leader in the field of testing and measurement, helping electronics OEMs and suppliers alike bring products to market to fit industry standards and specifications. Keysight specializes in the communications market, but also supplies into the government, automotive, industrial, and semiconductor manufacturing markets. Keysight's solutions include testing tools, analytical software, and services. The firm's stated objective is to reduce time to market and improve efficiency at its more than 30,000 customers.
Read more on KEYS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
